Vaccine value profile for norovirus

George Armah,Ben A Lopman,Jan Vinjé,Miguel O'Ryan,Claudio F Lanata,Michelle Groome,Jared Ovitt,Caroline Marshall,Elizabeth Sajewski,Mark S Riddle

DOI: https://doi.org/10.1016/j.vaccine.2023.03.034

IF: 4.169

2023-11-03

Vaccine

Abstract:Norovirus is attributed to nearly 1 out of every 5 episodes of diarrheal disease globally and is estimated to cause approximately 200,000 deaths annually worldwide, with 70,000 or more among children in developing countries. Noroviruses remain a leading cause of sporadic disease and outbreaks of acute gastroenteritis even in industrialized settings, highlighting that improved hygiene and sanitation alone may not be fully effective in controlling norovirus. Strengths in global progress towards a Norovirus vaccine include a diverse though not deep pipeline which includes multiple approaches, including some with proven technology platforms (e.g., VLP-based HPV vaccines). However, several gaps in knowledge persist, including a fulsome mechanistic understanding of how the virus attaches to human host cells, internalizes, and induces disease.